Intracellular Th Stock Fundamentals
| ITCI Stock | USD 131.26 0.10 0.08% |
Intracellular Th fundamentals help investors to digest information that contributes to Intracellular's financial success or failures. It also enables traders to predict the movement of Intracellular Stock. The fundamental analysis module provides a way to measure Intracellular's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intracellular stock.
As of now, Intracellular's Research Development is increasing as compared to previous years. The Intracellular's current Income Tax Expense is estimated to increase to about 496.6 K, while Operating Income is projected to decrease to (122.6 M). Intracellular | Select Account or Indicator |
Intracellular Th Company Profit Margin Analysis
Intracellular's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Intracellular Profit Margin | (0.11) % |
Most of Intracellular's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intracellular Th is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Intracellular Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Intracellular Th has a Profit Margin of -0.1097%. This is 99.02% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is 91.36% lower than that of the firm.
Intracellular Th Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Intracellular's current stock value. Our valuation model uses many indicators to compare Intracellular value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intracellular competition to find correlations between indicators driving Intracellular's intrinsic value. More Info.Intracellular Th is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Intracellular's Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intracellular's earnings, one of the primary drivers of an investment's value.Intracellular Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intracellular's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intracellular could also be used in its relative valuation, which is a method of valuing Intracellular by comparing valuation metrics of similar companies.Intracellular is currently under evaluation in profit margin category among its peers.
Intracellular ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Intracellular's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Intracellular's managers, analysts, and investors.Environmental | Governance | Social |
Intracellular Fundamentals
| Return On Equity | -0.0858 | ||||
| Return On Asset | -0.0696 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 12.97 B | ||||
| Shares Outstanding | 106.33 M | ||||
| Shares Owned By Insiders | 2.47 % | ||||
| Shares Owned By Institutions | 96.79 % | ||||
| Number Of Shares Shorted | 2.31 M | ||||
| Price To Earning | (6.56) X | ||||
| Price To Book | 12.16 X | ||||
| Price To Sales | 20.50 X | ||||
| Revenue | 680.85 M | ||||
| Gross Profit | 387.77 M | ||||
| EBITDA | (116.72 M) | ||||
| Net Income | (74.68 M) | ||||
| Cash And Equivalents | 628.74 M | ||||
| Cash Per Share | 6.64 X | ||||
| Total Debt | 16.98 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 9.81 X | ||||
| Book Value Per Share | 10.81 X | ||||
| Cash Flow From Operations | (73.18 M) | ||||
| Short Ratio | 1.19 X | ||||
| Earnings Per Share | (0.72) X | ||||
| Target Price | 132.0 | ||||
| Number Of Employees | 860 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 13.96 B | ||||
| Total Asset | 1.37 B | ||||
| Retained Earnings | (1.69 B) | ||||
| Working Capital | 1.1 B | ||||
| Current Asset | 541.82 M | ||||
| Current Liabilities | 140.69 M | ||||
| Net Asset | 1.37 B |
About Intracellular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intracellular Th's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intracellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intracellular Th based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 57.7 M | 60.5 M | |
| Total Revenue | 680.9 M | 714.9 M | |
| Cost Of Revenue | 57 M | 45.3 M | |
| Stock Based Compensation To Revenue | 0.09 | 0.09 | |
| Sales General And Administrative To Revenue | 0.62 | 0.58 | |
| Research And Ddevelopement To Revenue | 0.35 | 0.33 | |
| Revenue Per Share | 6.60 | 6.93 | |
| Ebit Per Revenue | (0.17) | (0.18) |
Currently Active Assets on Macroaxis
When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:Check out Intracellular Piotroski F Score and Intracellular Altman Z Score analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.72) | Revenue Per Share | Quarterly Revenue Growth 0.508 | Return On Assets | Return On Equity |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.